ZSAN Insider Trading Activity and SEC Form 4 Filings
ZSAN insider trading summary
No open-market insider purchases or sales of Zosano Pharma Corp (ZSAN) have been reported on SEC Form 4 in the past 12 months.
Latest ZSAN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 6, 2022 | Steven Lo | Chief Executive Officer | Sell | $314 (442 @ $0.71) |
| Jun 6, 2022 | Christine Matthews | Chief Financial Officer | Sell | $58 (82 @ $0.71) |
| Mar 31, 2022 | Steven Lo | Chief Executive Officer | Sell | $5K (23,633 @ $0.21) |
| Mar 31, 2022 | Christine Matthews | Chief Financial Officer | Sell | $2K (8,116 @ $0.21) |
| Mar 31, 2022 | Donald J Kellerman | VP, Clinical Dev & Med Affairs | Sell | $842 (4,006 @ $0.21) |
| Nov 23, 2021 | Kenneth Greathouse | Director | Sell | $6K (10,000 @ $0.60) |
| Jun 4, 2021 | Hayley Lewis | See Remarks | Sell | $1K (1,709 @ $0.81) |
| Jun 4, 2021 | Christine Matthews | Chief Financial Officer | Sell | $1K (1,709 @ $0.81) |
| Jun 4, 2021 | Steven Lo | Chief Executive Officer | Sell | $11K (13,158 @ $0.81) |
| Jun 4, 2021 | Donald J Kellerman | VP, Clinical Dev & Med Affairs | Sell | $1K (1,709 @ $0.81) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.